Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis
Phase 1
Completed
- Conditions
- Peritoneal Carcinomatosis
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Genelux GmbH
- Target Recruit Count
- 9
- Registration Number
- NCT01443260
- Locations
- 🇩🇪
University Hospital Tuebingen, Tuebingen, Germany
Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Cancers (Solid Tumors)
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Genelux GmbH
- Target Recruit Count
- 43
- Registration Number
- NCT00794131
- Locations
- 🇬🇧
Royal Marsden Hospital, Surrey, United Kingdom
News
Genelux Advances Olvi-Vec Trials in Lung and Ovarian Cancer, Anticipates Key Data Readouts
Genelux is actively enrolling patients in a Phase 3 trial for platinum-resistant/refractory ovarian cancer, with topline results expected in the latter half of 2025.
Genelux Doses First Patient in Phase 2 Trial of Olvi-Vec for Recurrent NSCLC
Genelux has dosed the first patient in a Phase 2 clinical trial (VIRO-25) evaluating Olvi-Vec for recurrent non-small cell lung cancer (NSCLC).